国际呼吸杂志
國際呼吸雜誌
국제호흡잡지
INTERNATIONAL JOURNAL OF RESPIRATION
2014年
13期
980-983
,共4页
程璘令%刘雅雅%苏柱泉%刘君%冉丕鑫
程璘令%劉雅雅%囌柱泉%劉君%冉丕鑫
정린령%류아아%소주천%류군%염비흠
糖皮质醇激素%慢性阻塞性肺疾病急性加重期%肺功能
糖皮質醇激素%慢性阻塞性肺疾病急性加重期%肺功能
당피질순격소%만성조새성폐질병급성가중기%폐공능
Corticosteroid%Acute exacerbation of chronic obsrtuctive pulmonary disease%Lung function
目的 对影响糖皮质醇激素改善COPD急性加重期(AECOPD)患者肺功能的可能因素进行分析,鉴定出影响FEV1改善的相关因素.方法 实验分两组,实验组AECOPD患者接受甲基泼尼松1 mg· kg-1·d-1静脉滴注及其他常规治疗,对照组接受除激素以外的其他常规治疗,连续治疗1周.治疗前后对所有AECOPD患者进行诱导痰炎性细胞、炎性介质(IL-6和IL-8)、呼出气一氧化氮(FeNO)检测和肺功能的检测.利用单因素和多因素线性回归筛选FEV1改善值的影响因素.结果 AECOPD患者经激素治疗后FEV1改善值为(0.32±0.21) L[FEV1％pred改善率为(19.3±10.6)％],而对照组FEV1改善值为(0.13±0.09) L[FEV1％pred改善率为(6.8±5.1)％],两者差异有统计学意义.我们对影响激素改善FEV1值的可能因素,包括气道炎症指标(诱导痰中性粒细胞、嗜酸粒细胞、IL-6、IL-8和治疗前FeNO水平)、年龄、基础肺功能等进行分析,结果显示嗜酸粒细胞百分比、治疗前FeNO、IL-8与FEV1改善值呈正相关,相关系数分别为0.816、0.62和0.54,进一步分析提示诱导痰的嗜酸粒细胞百分比、治疗前FeNO是影响FEV1改善值的主要因素,诱导痰嗜酸粒细胞百分比比治疗前FeNO对FEV1改善值的影响意义更大.结论 嗜酸粒细胞百分比、基础FeNO可作为激素改善COPD患者FEV1的预测因素.
目的 對影響糖皮質醇激素改善COPD急性加重期(AECOPD)患者肺功能的可能因素進行分析,鑒定齣影響FEV1改善的相關因素.方法 實驗分兩組,實驗組AECOPD患者接受甲基潑尼鬆1 mg· kg-1·d-1靜脈滴註及其他常規治療,對照組接受除激素以外的其他常規治療,連續治療1週.治療前後對所有AECOPD患者進行誘導痰炎性細胞、炎性介質(IL-6和IL-8)、呼齣氣一氧化氮(FeNO)檢測和肺功能的檢測.利用單因素和多因素線性迴歸篩選FEV1改善值的影響因素.結果 AECOPD患者經激素治療後FEV1改善值為(0.32±0.21) L[FEV1％pred改善率為(19.3±10.6)％],而對照組FEV1改善值為(0.13±0.09) L[FEV1％pred改善率為(6.8±5.1)％],兩者差異有統計學意義.我們對影響激素改善FEV1值的可能因素,包括氣道炎癥指標(誘導痰中性粒細胞、嗜痠粒細胞、IL-6、IL-8和治療前FeNO水平)、年齡、基礎肺功能等進行分析,結果顯示嗜痠粒細胞百分比、治療前FeNO、IL-8與FEV1改善值呈正相關,相關繫數分彆為0.816、0.62和0.54,進一步分析提示誘導痰的嗜痠粒細胞百分比、治療前FeNO是影響FEV1改善值的主要因素,誘導痰嗜痠粒細胞百分比比治療前FeNO對FEV1改善值的影響意義更大.結論 嗜痠粒細胞百分比、基礎FeNO可作為激素改善COPD患者FEV1的預測因素.
목적 대영향당피질순격소개선COPD급성가중기(AECOPD)환자폐공능적가능인소진행분석,감정출영향FEV1개선적상관인소.방법 실험분량조,실험조AECOPD환자접수갑기발니송1 mg· kg-1·d-1정맥적주급기타상규치료,대조조접수제격소이외적기타상규치료,련속치료1주.치료전후대소유AECOPD환자진행유도담염성세포、염성개질(IL-6화IL-8)、호출기일양화담(FeNO)검측화폐공능적검측.이용단인소화다인소선성회귀사선FEV1개선치적영향인소.결과 AECOPD환자경격소치료후FEV1개선치위(0.32±0.21) L[FEV1％pred개선솔위(19.3±10.6)％],이대조조FEV1개선치위(0.13±0.09) L[FEV1％pred개선솔위(6.8±5.1)％],량자차이유통계학의의.아문대영향격소개선FEV1치적가능인소,포괄기도염증지표(유도담중성립세포、기산립세포、IL-6、IL-8화치료전FeNO수평)、년령、기출폐공능등진행분석,결과현시기산립세포백분비、치료전FeNO、IL-8여FEV1개선치정정상관,상관계수분별위0.816、0.62화0.54,진일보분석제시유도담적기산립세포백분비、치료전FeNO시영향FEV1개선치적주요인소,유도담기산립세포백분비비치료전FeNO대FEV1개선치적영향의의경대.결론 기산립세포백분비、기출FeNO가작위격소개선COPD환자FEV1적예측인소.
Objective To investigated impact factor on improvement in lung function of patients with AECOPD treated with systemic corticosteroids.Methods AECOPD patients in study group were administered 40 mg/d Methyllprednisolone by intravenous injection besides other routine therapy for 1 week,AECOPD patients in control group only accepted other routine therapy.Sputum induction,lung function test,inflammatory mediators and FeNO measurement were performed in all AECOPD patients before and post treatment.Impact factors on improvement in lung function of patients with AECOPD treated with systemic corticosteroids were screened by simple linear regression or multiple regression.Results Improvement in lung function of patients with AECOPD treated with systemic were (0.32± 0.21) L,and improvement of lung function in control group were (0.13±0.09) L.This improvement was highly significant.We investigate all impact factors (including neutrophils％,eosinophils％ in induced sputum,IL-6,IL-8,baseline FeNO,age and lung functions) on improvement in lung function of patients with AECOPD.The improvement in FEV1 was correlated with the percentage of eosinophils (r =0.816,P ＜0.05),baseline FeNO (r =0.62,P ＜0.05) and IL-8 (r =0.62,P ＜0.05),respectively.The future investigate show percentage of eosinophils in induced sputum and baseline FeNO are the major factors on improvement in lung function of patients with AECOPD and eosinophils％ in induced sputum is the most important factor.Conclusions Our study show percentage of eosinophils in induced sputum and baseline FeNO are the major factors on improvement in lung function of patients with AECOPD treated with systemic corticosteroids.
